Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

AskRx vs Maves

AskRx
Graded #430

Lower grade

vs+15.799999999999997
Maves
Graded #91

Higher grade

The verdict

Maves takes it — 71.6/100 to 55.8/100.

Maves grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Maves, operating under parent company Homera Health, is a performance-framed telehealth platform offering compounded semaglutide and tirzepatide for weight loss plus sermorelin for anti-aging, with…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueMaves +59
24
83
Dose & formulationAskRx +2
67
65
Clinical oversightAskRx +6
82
76
Labs & monitoringEven
52
52
FulfillmentAskRx +1
88
87
Contract termsMaves +35
20
55
AskRx · left barMaves · right bar

The numbers

MetricAskRxMaves
WeighScore55.8/10071.6/100
GradeCC
Scorecard rank#430#91
Semaglutide$349/mo (all doses, brand-name)$99/mo (starting dose, first-month rate, compounded)
Tirzepatide$299/mo (2.5 mg dose, brand-name)Not disclosed
CoverageAll 50 statesAll 50 states
Brand-name accessYesYes
Oral / sublingualInjection onlyInjection only
AskRx

Graded #430 · C

Strengths

  • Prescribes only FDA-approved brand-name GLP-1s, no compounded drugs
  • LegitScript approved and HIPAA compliant
  • Board-certified physicians trained in obesity medicine
  • Transparent dose-based pricing published on site
  • Available in all 50 states

Where it loses points

  • Cash-pay model; medication cost billed separately by the pharmacy
  • Does not dispense medication itself, so fulfillment depends on third-party pharmacies
  • No compounded lower-cost alternative offered
  • Specific list of supported states is not published
Maves

Graded #91 · C

Strengths

  • LegitScript Certified
  • Publishes the FDA compounded-medication disclaimer
  • $99/mo first-month intro pricing on semaglutide — among the most aggressive we track
  • All 50 states covered, stated explicitly
  • Both brand (Maves) and parent (Homera Health) disclosed for accountability

Where it loses points

  • 503A pharmacy partner not named (only 'licensed U.S. pharmacies')
  • Tirzepatide pricing not stated on the homepage — only listed as an offering
  • Named medical director / clinical leadership not disclosed
  • Refund and cancellation policy not detailed publicly
  • Corporate address and arbitration venue not disclosed

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard